Prostate Cancer News

SBRT Appears Effective for Oligometastatic Prostate Cancer

SBRT Appears Effective for Oligometastatic Prostate Cancer

Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.

Active Surveillance May Be a Good Option for Younger Men with Prostate Cancer

Active Surveillance May Be a Good Option for Younger Men with Prostate Cancer

The effect of age on outcomes in active surveillance is not well reported and requires further study.

First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer

First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer

Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Beverages Sweetened With Added Sugars May Increase the Risk of Prostate Cancer

Beverages Sweetened With Added Sugars May Increase the Risk of Prostate Cancer

Some prior evidence has linked increased sugar consumption to cancer development, but its impact on prostate cancer is unknown.

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk Prostate Cancer

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk Prostate Cancer

The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.

High-Intensity Focused Ultrasound Therapy May Improve Survival in Nonmetastatic Prostate Cancer

High-Intensity Focused Ultrasound Therapy May Improve Survival in Nonmetastatic Prostate Cancer

Focal therapy targets may potentially reduce adverse events and provide better cancer control, but previous studies have been limited in scope.

Enzalutamide Postpones Metastasis for a Subset of High-Risk Patients With Prostate Cancer

Enzalutamide Postpones Metastasis for a Subset of High-Risk Patients With Prostate Cancer

Treatment with enzalutamide decreased the risk of metastasis or death by 71% in patients diagnosed with nonmetastatic castration-resistant prostate cancer.

Prostate Cancer Vaccine Found Not To Improve Survival

Prostate Cancer Vaccine Found Not To Improve Survival

In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.

Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White

Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White

Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.

PET/CT Accurately Localizes Recurrent Prostate Cancer

PET/CT Accurately Localizes Recurrent Prostate Cancer

Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

A phase 3 trial involving men treated with radiotherapy for intermediate- or high-risk prostate cancer revealed no significant difference in biochemical disease-free survival.

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.

USPSTF 2012 Screening Recommendations May Have Affected Prostate Cancer Testing

USPSTF 2012 Screening Recommendations May Have Affected Prostate Cancer Testing

The impact of USPSTF recommendations on the incidence and management of prostate cancer have not yet been fully explored.

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

Following laparoscopic radical prostatectomy, men with posterior index tumors had 76% increased risk of biochemical recurrence vs those with anterior prostate tumors.

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

Men with Gleason 6 and Gleason 3+4 prostate cancer who undergo radical prostatectomy after a period on active surveillance have similar surgical outcomes.

Online Survey May Allow Patients With Prostate Cancer To Accurately Report Comorbidities

Online Survey May Allow Patients With Prostate Cancer To Accurately Report Comorbidities

The BMH online survey allows patients to enter comorbidity data at home prior to consultation.

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

The cause of death was prostate cancer among 18% vs 22% of patients receiving ADT vs ADT plus MP, respectively.

Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

Patients in both treatment arms had a PFS of about 9 months.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs